A connected approach to Human ADME studies
Human ADME studies are critical for understanding how a drug is absorbed, distributed, metabolised and excreted. Yet many programmes experience delays, increased costs and unnecessary complexity because radiolabelling, GMP manufacturing, regulatory activities, clinical operations and bioanalysis are managed by multiple providers.
Through the combined expertise of Arcinova and Quotient Sciences, sponsors can access an integrated pathway from early radiolabelling strategy through to clinical study execution and data generation.
Smarter decisions from the outset
Stronger alignment across disciplines
Reduced risk and rework
Accelerated development timelines
Simplify a complex development pathway
Our integrated approach helps you:
- Reduce handovers between suppliers
- Minimise technology transfer and associated risks
- Maintain continuity from development through to clinical execution
- Accelerate study timelines through coordinated project delivery
- Generate high-quality ADME data to support confident decision-making
End-to-end support for human ADME studies
Our capabilities include:
- Non-GMP and GMP 14C radiolabelling
- Clinical-grade API manufacture
- Regulatory support and dossier preparation
- Clinical supply management
- Human ADME and mass balance studies (through the Quotient Sciences network)
- Bioanalytical support
One Molecule. One Team. One Development Pathway.
From radiolabelling strategy and GMP manufacture to clinical studies and bioanalysis, Arcinova and Quotient Sciences provide the expertise, continuity and integrated support needed to reduce complexity, accelerate timelines and deliver successful Human ADME studies with confidence.